Citations

Showing 10 of 108083 citations.

Powassan virus postencephalitic parkinsonism
Mittal, Shivam Om , Hassan, Anhar , Sanchez, Joyce L. , Robertson, Carrie E. , Sanchez, Joyce, Robertson, Carrie E , Mittal, Shivam Om

Mayo Clinic

Neurology Clinical Practice | December 11, 2017 | Volume: 7 | Issue: 6 | Pages: 527-530

10.1212/cpj.0000000000000391 | PMID 29431163 Get It

King-Devick Test identifies real-time concussion and asymptomatic concussion in youth athletes
Dhawan, Priya S., Leong, Danielle, Tapsell, Lisa, Starling, Amaal J. , Galetta, Steven , Balcer, Laura J. , Overall, Trenton L., Adler, Jennifer S. , Halker-Singh, Rashmi B., Vargas, Bert B., Galetta, Steven L, Dodick, David, Dodick, David W.

Mayo Clinic

Neurology Clinical Practice | December 11, 2017 | Volume: 7 | Issue: 6 | Pages: 464-473

10.1212/cpj.0000000000000381 | PMID 29431168 Get It

Improving Colorectal Cancer Screening Through Clinical Systems Redesign
Chaudhry, Rajeev , Scheitel, Sidna M., Kottke, Thomas E.

Mayo Clinic

Baylor University Medical Center Proceedings | December 11, 2017 | Volume: 16 | Issue: 3 | Pages: 346-346

10.1080/08998280.2003.11927924 | PMID 16278708 Get It

Neoadjuvant systemic therapy for regionally advanced melanoma
Jakub, James W. , Racz, Jennifer M. , Hieken, Tina J. , Gonzalez, Alexandra B., Kottschade, Lisa A. , Yan, Yiyi , Block, M.S., Block, Mathew S, Hieken, Tina J , Jakub, James W , Markovic, Svetomir N.

Mayo Clinic

Journal of Surgical Oncology | December 11, 2017 | Volume: 117 | Issue: 6 | Pages: 1164-1169

10.1002/jso.24939 | PMID 29228467 Get It

BackgroundPatients with regionally advanced melanoma are at high risk of distant failure and unlikely to be cured by surgery alone. Neoadjuvant therapy may provide benefit in these patients.ObjectivesTo evaluate our experience with neoadjuvant systemic therapy in high‐risk stage III patients.MethodsRetrospective review of patients with advanced stage III disease who received neoadjuvant therapy between August 2009 and August 2016 at Mayo Clinic Rochester.ResultsTwenty‐three cases met our inclusion criteria, 16 with resectable disease and 7 with unresectable disease. No patients with resectable disease and one patient with borderline resectable disease progressed regionally, prohibiting surgical resection. Five of seven patients with unresectable disease were down‐staged to a resectable state. Six of twenty‐three (26%) had a CR and five are alive at last follow‐up. Fifteen of twenty three patients (65%) progressed with a median progression free survival of 11 months; however, the 5 year overall survival estimate was 84%.ConclusionsNeoadjuvant systemic therapy is a reasonable approach for patients with advanced but resectable/borderline resectable disease and the risk of losing regional control is low. Our data also suggest some patients with unresectable disease will be converted to resectable and a complete clinical response to treatment can be obtained in approximately one quater of patients.
RNA sequencing identifies gene regulatory networks controlling extracellular matrix synthesis in intervertebral disk tissues
Riester, Scott M. , Yang, Lin , Wang, Wei , Lin, Cong , Ali, Abdel‐Moneim Mohamed , Peck, Sun H. , Smith, Lachlan J. , Currier, Bradford L. , Clark, Michelle A. , Huddleston, P.M. , Krauss, William E. , Yaszemski, Michael J. , Bydon, Mohamad , Qu, Wenchun , Wijnen, André J. van , Lin, Yang , Cong, Lin, Mohamed Ali, Abdel-Moneim, Clark, Michelle, Huddleston, Paul, Krauss, William, Larson, Annalise N, van Wijnen, Andre J , Morrey, Mark E. , Abdel, Matthew P. , Larson, A. Noelle , Nassr, Ahmad , Huddleston, Paul M

Mayo Clinic

Journal of Orthopaedic Research | December 11, 2017 | Volume: 36 | Issue: 5 | Pages: 1356-1369

10.1002/jor.23834 | PMID 29227558 Get It

ABSTRACTDegenerative disk disease of the spine is a major cause of back pain and disability. Optimization of regenerative medical therapies for degenerative disk disease requires a deep mechanistic understanding of the factors controlling the structural integrity of spinal tissues. In this investigation, we sought to identify candidate regulatory genes controlling extracellular matrix synthesis in spinal tissues. To achieve this goal we performed high throughput next generation RNA sequencing on 39 annulus fibrosus and 21 nucleus pulposus human tissue samples. Specimens were collected from patients undergoing surgical discectomy for the treatment of degenerative disk disease. Our studies identified associations between extracellular matrix genes, growth factors, and other important regulatory molecules. The fibrous matrix characteristic of annulus fibrosus was associated with expression of the growth factors platelet derived growth factor beta (PDGFB), vascular endothelial growth factor C (VEGFC), and fibroblast growth factor 9 (FGF9). Additionally we observed high expression of multiple signaling proteins involved in the NOTCH and WNT signaling cascades. Nucleus pulposus extracellular matrix related genes were associated with the expression of numerous diffusible growth factors largely associated with the transforming growth signaling cascade, including transforming factor alpha (TGFA), inhibin alpha (INHA), inhibin beta A (INHBA), bone morphogenetic proteins (BMP2, BMP6), and others. Clinical significance: this investigation provides important data on extracellular matrix gene regulatory networks in disk tissues. This information can be used to optimize pharmacologic, stem cell, and tissue engineering strategies for regeneration of the intervertebral disk and the treatment of back pain. © 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 36:1356–1369, 2018.
Isolated tricuspid regurgitation: outcomes and therapeutic interventions
Fender, Erin A. , Zack, Chad, Nishimura, Rick A., Zack, Chad J

Mayo Clinic

Heart | December 11, 2017 | Volume: 104 | Issue: 10 | Pages: 798-806

10.1136/heartjnl-2017-311586 | PMID 29229649 Get It

Isolated tricuspid regurgitation (TR) can be caused by primary valvular abnormalities such as flail leaflet or secondary annular dilation as is seen in atrial fibrillation, pulmonary hypertension and left heart disease. There is an increasing recognition of a subgroup of patients with isolated TR in the absence of other associated cardiac abnormalities. Left untreated isolated TR significantly worsens survival. Stand-alone surgery for isolated TR is rarely performed due to an average operative mortality of 8%–10% and a paucity of data demonstrating improved survival. When surgery is performed, valve repair may be preferred over replacement; however, there is a risk of significant recurrent regurgitation after repair. Existing society guidelines do not fully address the management of isolated TR. We propose that patients at low operative risk with symptomatic severe isolated TR and no reversible cause undergo surgery prior to the onset of right ventricular dysfunction and end-organ damage. For patients at increased surgical risk novel percutaneous interventions may offer an alternative treatment but further research is needed. Significant knowledge gaps remain and future research is needed to define operative outcomes and provide comparative data for medical and surgical therapy.
Faculty Opinions recommendation of Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
Fernández-Zapico, Martín E.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | December 11, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.732091698.793539857 Get It

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Herrera, Alex F. , Moskowitz, Alison J. , Bartlett, Nancy L. , Ramchandren, Radhakrishnan , Feldman, Tatyana , LaCasce, Ann S. , Ansell, Stephen M. , Moskowitz, Craig H. , Fenton, Keenan , Ogden, Carol Anne, Zhang, Qu , Kato, Kazunobu, Campbell, Mary S., Advani, Ranjana H. , Bartlett, Nancy L , Advani, Ranjana H , Vose, Julie M. , Taft, David R.

Mayo Clinic

Blood | December 11, 2017 | Volume: 131 | Issue: 11 | Pages: 1183-1194

10.1182/blood-2017-10-811224 | PMID 29229594 Get It

Key Points BV and Nivo were well-tolerated in patients with R/R HL, with less than 10% of patients treated with systemic steroids for immune-related AEs. The complete response rate was 61% (82% objective response rate), and patients were able to undergo stem cell transplant without adverse impact.
A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure
Kawakami, Rika , Lee, Candace Y.W., Bailey, Kent R. , Schirger, John A., Chen, Horng H. , Benike, Sherry L., Cannone, Valentina , Martín, Fernando L., Sangaralingham, S. Jeson , Ichiki, Tomoko , Burnett, John C. , Kawakami, Rika , Scott, Christopher G. , Sangaralingham, S. Jeson , Kawakami, Rika

Mayo Clinic

Clinical Pharmacology & Therapeutics | December 11, 2017 | Volume: 104 | Issue: 3 | Pages: 546-552

10.1002/cpt.974 | PMID 29226471 Get It

Cenderitide is a novel designer natriuretic peptide (NP) composed of C‐type natriuretic peptide (CNP) fused to the C‐terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide was engineered to coactivate the two NP receptors, particulate guanylyl cyclase (pGC)‐A and ‐B. The rationale for its design was to achieve the renal‐enhancing and antifibrotic properties of dual receptor activation, but without clinically significant hypotension. Here we report the first clinical trial on the safety, tolerability, and cyclic guanosine monophosphate (cGMP) activating properties of Cenderitide in subjects with stable heart failure (HF). Four‐hour infusion of Cenderitide was safe, well‐tolerated, and significantly increased plasma cGMP levels and urinary cGMP excretion without adverse effects with no change in blood pressure. Thus, Cenderitide has a favorable safety profile and expected pharmacological effects in stable human HF. Our results support further investigations of Cenderitide in HF as a potential future cGMP‐enhancing therapeutic strategy.
Editorial: patient assessment of constipation‐symptoms (PAC‐SYM) questionnaire has a minimal important difference
Saito, Yuri A. , Camilleri, Michael , Saito, Y A , Camilleri, M

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 11, 2017 | Volume: 47 | Issue: 1 | Pages: 138-139

10.1111/apt.14389 | PMID 29226416 Get It

Linked ContentThis article is linked to Yiannakou et al paper. To view this article visit https://doi.org/10.1111/apt.14349.